Catalog No.
KDD82501
Description
PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human EPHA3 has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Ifabotuzumab in the sample competitively binds to the pre-coated protein with biotin-labeled Ifabotuzumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Ifabotuzumab bound in the initial step. The color development is stopped and the intensity of the color is measured.
Applications
Used for the quantitative determination of Ifabotuzumab concentration in serum and plasma.
Detection method
Colorimetric
Sample type
Plasma, Serum
Assay type
Quantitative
Range
12.5 - 800 ng/mL
Sensitivity
18.17 ng/mL
Precision
Intra-Assay Precision (Precision within an assay): <20%
Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): <20%
Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.
|
|
Intra-Assay Precision |
Inter-Assay Precision |
||||
|
Sample |
1 |
2 |
3 |
1 |
2 |
3 |
|
n |
16 |
16 |
16 |
24 |
24 |
24 |
|
Mean (ng/mL) |
334.6 |
88.8 |
28.1 |
314.6 |
81.8 |
18.3 |
|
Standard deviation |
18.8 |
8.0 |
5.0 |
34.0 |
9.3 |
3.5 |
|
CV (%) |
5.6 |
9.0 |
17.9 |
10.8 |
11.3 |
19.0 |
Recovery
80-120%
Shipping
2-8 ℃
Stability and Storage
When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.
Alternative Names
Fibatuzumab, KB-004, , CAS: 1234137-51-9
Background
Ifabotuzumab (formerly KB004) is a first-in-class therapeutic non-fucosylated IgG1 (human f-allotype) monoclonal antibody being developed by Humanigen (formerly KaloBios Pharmaceuticals) for the treatment of cancer. The drug was licensed from the Ludwig Institute for Cancer Research. The molecule contains a human antibody constant region with V-regions that are 92% identical to human germ-line sequences. Ifabotuzumab targets the ephrin type-A receptor 3 (EphA3) tyrosine kinase. In non-clinical studies, Ifabotuzumab demonstrated potent ex-vivo cell killing of EphA3+ tumor cells obtained from patients with hematologic malignancies.
For research use only. Not for human or drug use.
